Navigation Links
Shining the soothing light
Date:10/21/2013

Almost all patients suffering from head and neck squamous cell carcinoma (HNSCC) develop canker sores, a complication resulting from different modalities of treatment, namely stem cell transplantation, chemotherapy, and radiotherapy. Canker sore is divided in five grades (zero to four) by the World Health Organization (WHO), with severe cases (grades 3 and 4) being associated with pain, weight loss, poor quality of life, and higher hospital costs due to increased healthcare needs. Severe canker sore can also lead to treatment interruption, which may decrease the patient's chances of surviving the cancer.

No effective preventative strategy is currently available for canker sore, but prospective trials of low-level laser therapy (LLLT) done in HNSCC patients undergoing chemoradiotherapy showed promising results. However, additional trials detected a high incidence of canker sore among patients, leaving the question of whether LLLT can effectively prevent canker sore still open.

Now, a group of scientists led by Dr. Heliton Spindola Antunes at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil, has successfully performed a definitive trial showing that LLLT reduces the occurrence of canker sore in HNSCC patients undergoing concurrent chemoradiotherapy and improves patient's quality of life.

The trial was performed with 94 HNSCC patients undergoing chemoradiotherapy. They were divided into two groups of 47 individuals, one of which received LLLT while the other received placebo. Researchers observed a significant difference in the incidence of canker sore grades 3 and 4 between groups. For instance, while in the group of patients receiving LLLT only three patients developed severe cases of canker sore, in the group receiving the placebo this number was 19. There were also significant differences in the absence of canker sore (grades 0-1), with the LLLT group having 59.6% of patients free of canker sore as opposed to 21.3% in the placebo group. The LLLT group had less severe oral pain and, as a result, used fewer opioid analgesics. They were also less likely to require gastrostomy (a surgical opening into the stomach for nutritional support) throughout the cancer treatment.

"For ethical reasons," says Dr Antunes, "all patients who developed canker sore grades 3 or 4 in the placebo arm were then offered the option of receiving LLLT. They all improved to grade 2 or lower, supporting the evidence that LLLT is an effective choice to prevent or treat canker sore in these patients."


'/>"/>

Contact: Heliton Spindola Antunes
hspindola@inca.gov.br
55-213-207-6597
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. Mother-Baby Sleep Experts Offer Tips for Soothing Crying Babies, Giving Exhausted Mothers Alternatives to Crying It Out
2. Soothing sounds during cataract surgery reduces patient anxiety
3. Cataract Patients Relax to a Soothing Beat, Study Says
4. Nationwide Title Clearing, Inc. Prepares for “Light the Night Walk” for Cancer Fundraising
5. Into Action Treatment Sponsors NOPE Annual Candlelight Vigil
6. Specialized Lighting Products Designed by Daylight Now Offered by Rehabmart.com
7. Deepak Chopra Introduces Dream Weaver App for Smartphones with Strobe Lights, Making It Easy to Experience the Benefits of Meditation & Deep Relaxation Automatically
8. Mesothelioma Awareness Day Sheds Light on Deadly Cancer
9. Joseph Gordon-Levitt’s “Don Jon” Spotlights the Health Problems with Porn
10. Go Healthy Next Announces the SaunaFix, a Portable Sauna Featuring Near Infrared Light Therapy
11. FHFA Highlights Homeowners HARP Refinancing: Eligibility Is Easier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , ... January 24, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... will enable customers to monitor, respond and protect their critical information assets and ...
(Date:1/24/2017)... ... ... His message has been heard by more than 100,000 students and adults across ... Feldman, has reached his biggest national audience yet: the three million daily readers of ... circulation in the country, and he hopes it will help spread his message and ...
(Date:1/24/2017)... ... January 24, 2017 , ... This Saturday, January 28, the BCFA ... very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & Sarah ... dim sum, and exhibitors offer a look at Chinese games, crafts & more. Festivities ...
(Date:1/24/2017)... Boston, MA (PRWEB) , ... January 24, 2017 ... ... What They Really Need to Thrive , Well-meaning studies such as the Fordham ... and schools can better serve top students, such as including gifted or high-achieving ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: ... , Sharon Kleyne, the nation’s foremost water advocate and host of the nationally ... Health on Voice America, once again welcomed one of her favorite guests and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
(Date:1/23/2017)... ROCKVILLE, Md. , Jan. 23, 2017 /PRNewswire/ ... to advancing a new standard in respiratory care, ... Committee for Orphan Medicinal Products has granted Orphan ... the treatment of Bronchiolitis Obliterans Syndrome (BOS).  ... Drug Designation from the EMA to treat patients ...
(Date:1/23/2017)... Jan. 23, 2017  Based on its recent ... Sullivan recognizes Ansell, a global leader in protection ... Company of the Year Award. Ansell,s comprehensive product ... wide global footprint have placed it in a ... market. The Company,s established product line and robust ...
Breaking Medicine Technology: